Sas
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Sas as PDF for free.
More details
- Words: 2,342
- Pages: 6
SAS India Launches SAS 9 After $1bn R&D Effort By Hinesh Jethwani Mumbai, Mar 31, 2004
As part of its global launch initiative, SAS unveiled SAS 9 in India today, culminating a $1 billion R&D effort spread over the last four years, which is being touted as the biggest launch ever undertaken by the company in its 28-year history. SAS 9 is being branded as a faster, more efficient and easier to use solution, than its predecessors. It can accommodate changing organizational needs without any loss of efficiency. The new platform connects all SAS applications so they work together transparently, and it also communicates with other data sources and programs. Speaking to CXOtoday on the occasion of the launch, Bill Gibson, chief technology officer, SAS Asia Pacific, said, "Data duplication is a prime issue which has to be dealt with today. As far as extracting data from disparate sources goes, SAS 9 will effectively create a warehouse, where objects will be standardized for further statistical analysis. Amongst the early implementers of the SAS 9 platform, is LG Home Shopping network in Korea, where multiple data sources like SAP, Siebel and Informix were effectively harnessed to generate results."
SAS 9 consists of an Enterprise ETL server, Intelligent Storage, Enterprise BI server, and SAS solutions. According to Don Cooper Williams, director - marketing & alliances, SAS Asia-Pacific, "The SAS Intelligence platform will provide users a single view of the enterprise, originating at the desktop level, and spreading through the mobile user group right up to the CIO level, unlike others that provide only historical data.” "SAS 9 includes the SAS Intelligence Platform, a broad set of integrated software for data integration, easyto-use business reporting and unparalleled analytics. It also boasts enhancement of the most tightly integrated optimization and predictive analytics capabilities available, making it easier to answer complex questions that cannot be addressed by traditional BI,” added Williams. To support this growth, SAS India aims to expand its direct customer facing team and alliance partners. In the past, SAS India has made successful inroads into the BFSI, Telecom and Pharmaceutical verticals where there has been high demand for BI solutions. Going forward, SAS India expects Retail and Manufacturing to be the additional growth drivers. Vivek Gokarn, Managing Director & CEO, SAS India said, "SAS 9 will be available to our existing customers as a free upgrade. We grew 30% last year in 2003 and SAS 9 is expected to drive this pace of growth to an even higher level by 40%, by actually expanding the market for BI solutions.” SAS India plans to impart training on SAS 9 solutions to core members of its Alliance partners who in turn would train close to 100+ executives in implementation across the country through the year. The future potential of the BI market in India, as per a Frost & Sullivan report is reflected in a CAGR of
33.9%, wherein India figures will be US $53.2 million by 2008, up from US $15.9 million in 2003. The company has over 120 installations in the country, and recent key customer wins include IDBI, Citibank N.A., HSBC and I-Gate. SAS India currently has consulting alliances with, PricewaterhouseCoopers, TCS, Tata Infotech, Satyam and MindTree Consulting. Its hardware alliance partners include HP, Sun and IBM.
SAS Drug Development Enchanced By CXOtoday Staff Mumbai, Jun 22, 2006
Business Intelligence (BI) vendor SAS has rehashed its flagship life sciences offering SAS Drug Development, adding new genomic-analysis capabilities in it to make it easier for pharmaceutical companies to analyze genetic data and incorporate the analysis into new drug applications. SAS Drug Development is a data management and analysis solution for pharmaceutical, medical device and biotechnology firms. The vendor has brought in more than 90 processes for genomic and proteomic-specific molecular analyses, which address the key areas such as genetics, microarrays and proteomics. The solution apparently provides a customizable, collaborative system for accurate and effective transformation of potential human drugs, biological products or medical devices from discovery or "proof of concept" stage into a medical product.
SAS says that the enhancement would also enable organizations to easily incorporate molecular information into clinical decision-making while allowing life science organizations to facilitate regulatory compliance, meet requirements for traceability of analytical results and simplify global collaboration. Commenting on the new updated version of SAS Drug Development, Dr. Alan Louie, Research Director at Health Industry Insights, an IDC Company said, "As retrospective biomarker data begins to be developed for Phase 4 drug testing, these new molecular analysis capabilities will help to accelerate knowledge capture, analysis and dissemination across the pharmaceutical development pipeline."
Accenture and SAS Increase Collaboration for BI By CXOtoday Staff Mumbai, Mar 6, 2007
Accenture plans to expand its business intelligence services through increased collaboration with SAS, a provider of business intelligence (BI) software and services. This relationship will help Accenture deliver proven, repeatable solutions and create additional specialized capabilities to meet the increased demand for business intelligence services currently provided to clients through its Accenture Information Management Services (AIMS) organization. For SAS, the relationship will help accelerate growth of the company's global BI software revenue by leveraging Accenture's investment in sales, marketing, training, research and development, and expertise in industry and business processes. "We are clearly seeing an increased demand for business intelligence services as organizations seek higher performance by collecting and analyzing internal and external data," said Royce Bell, Chief Executive Officer of Accenture Information Management Services. "By striking a closer relationship with a market-leading enterprise business intelligence software vendor, we will be able to provide our clients with even more skills and scale than previously possible."
"Business intelligence solutions and services are clearly the next growth area in information technology. By leveraging our mutual strengths in software, services and business expertise, we will be better able to take advantage of global strategic BI opportunities," said Jim Davis, Senior Vice President and Chief Marketing Officer of SAS. "The breadth of SAS' enterprise intelligence platform and industry focused solutions coupled with Accenture's ability to provide additional customization, implementation services and global delivery, will allow customers to address key business and technology pains associated with information management more quickly and effectively." Accenture and SAS have successfully teamed together over the last 10 years to provide business intelligence solutions in the analytics area where companies are seeking to get more insight and value out of their data, a news release said here today. This expanded relationship will help provide a foundation for Accenture and SAS to further develop, market, sell and deliver global industry solutions for businesses via a comprehensive and united approach and set of resources, it added. According to Henry Morris, Group VP for Integration, Development and Application Strategies at IDC, a leading analyst firm: "This is a positive move for both companies, each with a demonstrated record of success in the field of analytics. SAS' commitment to industry solutions and an intelligence platform is complemented by Accenture's capabilities to explain the benefits to senior executives in the language of their vertical industry and to provide the skilled personnel required for delivery. The agreement should benefit both firms and should advance the penetration of analytics across industries and across regions." Accenture plans to expand its SAS business intelligence capabilities, specifically around the SAS Enterprise
Intelligence Platform, which is the foundation for SAS' targeted business solutions that support enterprise intelligence, customer intelligence, financial intelligence, supply chain intelligence, as well as technology solutions for various vertical markets, such as financial services, life sciences, health care, retail, manufacturing and others.
SAS® SOLUTIONS FOR LIFE SCIENCES With so many challenges facing the life sciences industry – pricing pressures, pipeline pressures, impending patent expirations, the soaring cost of developing new drugs – the strength of these companies as well as the intellectual property they need to improve the health of the public is being threatened. While the focus seems to be shifting to personalized medicine – the right drug for the right patient – personalized drugs will most likely mandate significant changes to life sciences companies' business practices. How can drug companies remain profitable so they can continue to deliver the best drugs to the public? In the Spotlight
Preparing for the New Health Industry Agenda: How Will it Impact You?
Watch this on-demand Webcast featuring Newt Gingrich to find out how the 21st century health services agenda will impact you and your business.
HCI 100: 100 Companies by Revenue Healthcare Informatics June 2007 (PDF: 426KB)
• • • •
SAS solutions for life sciences companies optimize the flow of valuable scientific and operational data within these companies – helping them bring therapies to market faster and more profitably. SAS is the only company that offers an end-to-end solution to drive efficiencies throughout every stage of a drug's lifecycle: from discovery, through development, commercialization and beyond. SAS has a deep commitment to the development of data standards in life sciences. Anticipating the movement of the industry and its governing regulatory bodies toward standards, SAS has developed technology available today to support the emerging CDISC data models. Globally recognized as the industry leader in analytics, the de facto standard for clinical data analysis, the FDA standard for electronic submissions and the choice of 100% percent of the Fortune 500 life sciences companies, SAS assures accurate, consistent and reliable analysis of pharmaceutical research data. By providing a way to warehouse, manage and analyze your data more efficiently and effectively, SAS solutions enable life sciences companies to:
Transform biomedical data into clinical insights quickly. Analyze operational data to manage risk and maximize profits. Convert intellectual property from discoveries into effective drug treatments.
Integrate scientific, customer, and operational data to make research and commercialization programs even more successful. A suite of solutions to help bring your drug to market successfully SAS understands that each stage of bringing a drug to market has unique needs. SAS Solutions for Life Sciences distinctly address the needs of each of these unique stages. Powered by SAS technology, SAS Solutions for Life Sciences are also designed to work collaboratively, enabling you to combine solutions as needed in order to bring your drug to market more quickly and
successfully. •
•
SAS Drug Development provides a centralized, integrated system for managing, analyzing, reporting and reviewing clinical research information. The solution enables life sciences organizations to get better products to market faster by more effectively assessing the safety and efficacy of research compounds and by facilitating collaboration across trials, phases and therapeutic areas. SAS for Life Sciences Sales and Marketing delivers unique customer insights that life sciences firms can use to execute more efficient marketing, sales and service strategies. SAS provides proven analytics to power sales and marketing execution.
In addition to SAS Solutions for Life Sciences, SAS offers many other focused solutions and technologies for your enterprise. Taken together, these solutions give you THE POWER TO KNOW®. SAS® AND THE CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM (CDISC) The importance of data standards Data standards are a critical component in the quest to improve global public health. Inefficiencies in the collection, processing and analysis of patient and health-related information drive up the cost of research and development for life sciences companies as well as negatively impact the cost and quality of healthcare delivery for patients and consumers. In the Spotlight
Clinical Integration and CDISC Learn how SAS can help you standardize clinical information using CDISC.
• • • • • •
The solution is to leverage data standards like CDISC to provide more efficient and effective use of medical information by all members of the healthcare and life sciences ecosystem. SAS CDISC participation With a deep commitment to the development and implementation of data standards in life sciences, SAS has been a member and ardent supporter of CDISC since 2000. SAS' involvement in CDISC includes:
CDISC Board of Directors participation. CDISC Industry Advisory Board participation. CDISC Data Model Team participation for ODM, ADaM, SDS and CRT-DDS (define.xml). Participation in strategic CDISC development initiatives such as the Biomedical Research Integrated Domain Group (BRIDG) model. Interoperability demonstrations in software "connectathons." Collaborations in CDISC Interchanges and other projects to explore the interoperability of CDISC data models.
• Support of CDISC training and implementation activities. SAS software support for CDISC standards In addition to helping define CDISC standards, SAS is making certain that our products and solutions support the implementation of CDISC data standards. SAS®9 includes a component called PROC CDISC that enables organizations running SAS programs to work with CDISC structured data. PROC CDISC supports bi-directional conversion of data content contained in a CDISC ODM XML document to and from SAS-accessible data sources. The current version of PROC CDISC also supports content validation of SAS-accessible data sources to the CDISC SDTM data domain definitions. See www.cdisc.org for details on individual format descriptions.
CDISC standards such as SDTM, ODM, LAB and ADaM can be effectively implemented in solutions like SAS Drug Development and SAS DI Studio, and we're currently exploring additional ways that these standard processes and data structures can be utilized within our software. The SAS XML Libname Engine has been enhanced in SAS 9.1.3 to natively read and write CDISC ODM file content. Using the SAS XML Libname Engine, any data content accessible to SAS may be converted to a CDISC ODM XML document, or conversely, any content in a CDISC ODM XML document may be converted to a SAS dataset or other SAS-accessible data source. SAS CDISC implementation services In addition to providing CDISC support within our software, SAS consultants are ready to help your organization implement CDISC standards to drive efficiencies in your clinical development processes. Registered solution provider SAS is recognized by CDISC as a CDISC Registered Solution Provider. Solution providers are qualified consultants, systems integrators and subject-matter experts believed by CDISC to have sufficient knowledge and experience implementing the various CDISC standards. Glossary ADaM CDISC CRT-DDS LAB ODM SDS SDTM XML
Analysis Dataset Model Clinical Data Interchange Standards Consortium Case Report Tabulation Data Definition Specification Laboratory Data Model Operational Data Model Submission Data Standards Study Data Tabulation Model eXtensible Markup Language
As part of its global launch initiative, SAS unveiled SAS 9 in India today, culminating a $1 billion R&D effort spread over the last four years, which is being touted as the biggest launch ever undertaken by the company in its 28-year history. SAS 9 is being branded as a faster, more efficient and easier to use solution, than its predecessors. It can accommodate changing organizational needs without any loss of efficiency. The new platform connects all SAS applications so they work together transparently, and it also communicates with other data sources and programs. Speaking to CXOtoday on the occasion of the launch, Bill Gibson, chief technology officer, SAS Asia Pacific, said, "Data duplication is a prime issue which has to be dealt with today. As far as extracting data from disparate sources goes, SAS 9 will effectively create a warehouse, where objects will be standardized for further statistical analysis. Amongst the early implementers of the SAS 9 platform, is LG Home Shopping network in Korea, where multiple data sources like SAP, Siebel and Informix were effectively harnessed to generate results."
SAS 9 consists of an Enterprise ETL server, Intelligent Storage, Enterprise BI server, and SAS solutions. According to Don Cooper Williams, director - marketing & alliances, SAS Asia-Pacific, "The SAS Intelligence platform will provide users a single view of the enterprise, originating at the desktop level, and spreading through the mobile user group right up to the CIO level, unlike others that provide only historical data.” "SAS 9 includes the SAS Intelligence Platform, a broad set of integrated software for data integration, easyto-use business reporting and unparalleled analytics. It also boasts enhancement of the most tightly integrated optimization and predictive analytics capabilities available, making it easier to answer complex questions that cannot be addressed by traditional BI,” added Williams. To support this growth, SAS India aims to expand its direct customer facing team and alliance partners. In the past, SAS India has made successful inroads into the BFSI, Telecom and Pharmaceutical verticals where there has been high demand for BI solutions. Going forward, SAS India expects Retail and Manufacturing to be the additional growth drivers. Vivek Gokarn, Managing Director & CEO, SAS India said, "SAS 9 will be available to our existing customers as a free upgrade. We grew 30% last year in 2003 and SAS 9 is expected to drive this pace of growth to an even higher level by 40%, by actually expanding the market for BI solutions.” SAS India plans to impart training on SAS 9 solutions to core members of its Alliance partners who in turn would train close to 100+ executives in implementation across the country through the year. The future potential of the BI market in India, as per a Frost & Sullivan report is reflected in a CAGR of
33.9%, wherein India figures will be US $53.2 million by 2008, up from US $15.9 million in 2003. The company has over 120 installations in the country, and recent key customer wins include IDBI, Citibank N.A., HSBC and I-Gate. SAS India currently has consulting alliances with, PricewaterhouseCoopers, TCS, Tata Infotech, Satyam and MindTree Consulting. Its hardware alliance partners include HP, Sun and IBM.
SAS Drug Development Enchanced By CXOtoday Staff Mumbai, Jun 22, 2006
Business Intelligence (BI) vendor SAS has rehashed its flagship life sciences offering SAS Drug Development, adding new genomic-analysis capabilities in it to make it easier for pharmaceutical companies to analyze genetic data and incorporate the analysis into new drug applications. SAS Drug Development is a data management and analysis solution for pharmaceutical, medical device and biotechnology firms. The vendor has brought in more than 90 processes for genomic and proteomic-specific molecular analyses, which address the key areas such as genetics, microarrays and proteomics. The solution apparently provides a customizable, collaborative system for accurate and effective transformation of potential human drugs, biological products or medical devices from discovery or "proof of concept" stage into a medical product.
SAS says that the enhancement would also enable organizations to easily incorporate molecular information into clinical decision-making while allowing life science organizations to facilitate regulatory compliance, meet requirements for traceability of analytical results and simplify global collaboration. Commenting on the new updated version of SAS Drug Development, Dr. Alan Louie, Research Director at Health Industry Insights, an IDC Company said, "As retrospective biomarker data begins to be developed for Phase 4 drug testing, these new molecular analysis capabilities will help to accelerate knowledge capture, analysis and dissemination across the pharmaceutical development pipeline."
Accenture and SAS Increase Collaboration for BI By CXOtoday Staff Mumbai, Mar 6, 2007
Accenture plans to expand its business intelligence services through increased collaboration with SAS, a provider of business intelligence (BI) software and services. This relationship will help Accenture deliver proven, repeatable solutions and create additional specialized capabilities to meet the increased demand for business intelligence services currently provided to clients through its Accenture Information Management Services (AIMS) organization. For SAS, the relationship will help accelerate growth of the company's global BI software revenue by leveraging Accenture's investment in sales, marketing, training, research and development, and expertise in industry and business processes. "We are clearly seeing an increased demand for business intelligence services as organizations seek higher performance by collecting and analyzing internal and external data," said Royce Bell, Chief Executive Officer of Accenture Information Management Services. "By striking a closer relationship with a market-leading enterprise business intelligence software vendor, we will be able to provide our clients with even more skills and scale than previously possible."
"Business intelligence solutions and services are clearly the next growth area in information technology. By leveraging our mutual strengths in software, services and business expertise, we will be better able to take advantage of global strategic BI opportunities," said Jim Davis, Senior Vice President and Chief Marketing Officer of SAS. "The breadth of SAS' enterprise intelligence platform and industry focused solutions coupled with Accenture's ability to provide additional customization, implementation services and global delivery, will allow customers to address key business and technology pains associated with information management more quickly and effectively." Accenture and SAS have successfully teamed together over the last 10 years to provide business intelligence solutions in the analytics area where companies are seeking to get more insight and value out of their data, a news release said here today. This expanded relationship will help provide a foundation for Accenture and SAS to further develop, market, sell and deliver global industry solutions for businesses via a comprehensive and united approach and set of resources, it added. According to Henry Morris, Group VP for Integration, Development and Application Strategies at IDC, a leading analyst firm: "This is a positive move for both companies, each with a demonstrated record of success in the field of analytics. SAS' commitment to industry solutions and an intelligence platform is complemented by Accenture's capabilities to explain the benefits to senior executives in the language of their vertical industry and to provide the skilled personnel required for delivery. The agreement should benefit both firms and should advance the penetration of analytics across industries and across regions." Accenture plans to expand its SAS business intelligence capabilities, specifically around the SAS Enterprise
Intelligence Platform, which is the foundation for SAS' targeted business solutions that support enterprise intelligence, customer intelligence, financial intelligence, supply chain intelligence, as well as technology solutions for various vertical markets, such as financial services, life sciences, health care, retail, manufacturing and others.
SAS® SOLUTIONS FOR LIFE SCIENCES With so many challenges facing the life sciences industry – pricing pressures, pipeline pressures, impending patent expirations, the soaring cost of developing new drugs – the strength of these companies as well as the intellectual property they need to improve the health of the public is being threatened. While the focus seems to be shifting to personalized medicine – the right drug for the right patient – personalized drugs will most likely mandate significant changes to life sciences companies' business practices. How can drug companies remain profitable so they can continue to deliver the best drugs to the public? In the Spotlight
Preparing for the New Health Industry Agenda: How Will it Impact You?
Watch this on-demand Webcast featuring Newt Gingrich to find out how the 21st century health services agenda will impact you and your business.
HCI 100: 100 Companies by Revenue Healthcare Informatics June 2007 (PDF: 426KB)
• • • •
SAS solutions for life sciences companies optimize the flow of valuable scientific and operational data within these companies – helping them bring therapies to market faster and more profitably. SAS is the only company that offers an end-to-end solution to drive efficiencies throughout every stage of a drug's lifecycle: from discovery, through development, commercialization and beyond. SAS has a deep commitment to the development of data standards in life sciences. Anticipating the movement of the industry and its governing regulatory bodies toward standards, SAS has developed technology available today to support the emerging CDISC data models. Globally recognized as the industry leader in analytics, the de facto standard for clinical data analysis, the FDA standard for electronic submissions and the choice of 100% percent of the Fortune 500 life sciences companies, SAS assures accurate, consistent and reliable analysis of pharmaceutical research data. By providing a way to warehouse, manage and analyze your data more efficiently and effectively, SAS solutions enable life sciences companies to:
Transform biomedical data into clinical insights quickly. Analyze operational data to manage risk and maximize profits. Convert intellectual property from discoveries into effective drug treatments.
Integrate scientific, customer, and operational data to make research and commercialization programs even more successful. A suite of solutions to help bring your drug to market successfully SAS understands that each stage of bringing a drug to market has unique needs. SAS Solutions for Life Sciences distinctly address the needs of each of these unique stages. Powered by SAS technology, SAS Solutions for Life Sciences are also designed to work collaboratively, enabling you to combine solutions as needed in order to bring your drug to market more quickly and
successfully. •
•
SAS Drug Development provides a centralized, integrated system for managing, analyzing, reporting and reviewing clinical research information. The solution enables life sciences organizations to get better products to market faster by more effectively assessing the safety and efficacy of research compounds and by facilitating collaboration across trials, phases and therapeutic areas. SAS for Life Sciences Sales and Marketing delivers unique customer insights that life sciences firms can use to execute more efficient marketing, sales and service strategies. SAS provides proven analytics to power sales and marketing execution.
In addition to SAS Solutions for Life Sciences, SAS offers many other focused solutions and technologies for your enterprise. Taken together, these solutions give you THE POWER TO KNOW®. SAS® AND THE CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM (CDISC) The importance of data standards Data standards are a critical component in the quest to improve global public health. Inefficiencies in the collection, processing and analysis of patient and health-related information drive up the cost of research and development for life sciences companies as well as negatively impact the cost and quality of healthcare delivery for patients and consumers. In the Spotlight
Clinical Integration and CDISC Learn how SAS can help you standardize clinical information using CDISC.
• • • • • •
The solution is to leverage data standards like CDISC to provide more efficient and effective use of medical information by all members of the healthcare and life sciences ecosystem. SAS CDISC participation With a deep commitment to the development and implementation of data standards in life sciences, SAS has been a member and ardent supporter of CDISC since 2000. SAS' involvement in CDISC includes:
CDISC Board of Directors participation. CDISC Industry Advisory Board participation. CDISC Data Model Team participation for ODM, ADaM, SDS and CRT-DDS (define.xml). Participation in strategic CDISC development initiatives such as the Biomedical Research Integrated Domain Group (BRIDG) model. Interoperability demonstrations in software "connectathons." Collaborations in CDISC Interchanges and other projects to explore the interoperability of CDISC data models.
• Support of CDISC training and implementation activities. SAS software support for CDISC standards In addition to helping define CDISC standards, SAS is making certain that our products and solutions support the implementation of CDISC data standards. SAS®9 includes a component called PROC CDISC that enables organizations running SAS programs to work with CDISC structured data. PROC CDISC supports bi-directional conversion of data content contained in a CDISC ODM XML document to and from SAS-accessible data sources. The current version of PROC CDISC also supports content validation of SAS-accessible data sources to the CDISC SDTM data domain definitions. See www.cdisc.org for details on individual format descriptions.
CDISC standards such as SDTM, ODM, LAB and ADaM can be effectively implemented in solutions like SAS Drug Development and SAS DI Studio, and we're currently exploring additional ways that these standard processes and data structures can be utilized within our software. The SAS XML Libname Engine has been enhanced in SAS 9.1.3 to natively read and write CDISC ODM file content. Using the SAS XML Libname Engine, any data content accessible to SAS may be converted to a CDISC ODM XML document, or conversely, any content in a CDISC ODM XML document may be converted to a SAS dataset or other SAS-accessible data source. SAS CDISC implementation services In addition to providing CDISC support within our software, SAS consultants are ready to help your organization implement CDISC standards to drive efficiencies in your clinical development processes. Registered solution provider SAS is recognized by CDISC as a CDISC Registered Solution Provider. Solution providers are qualified consultants, systems integrators and subject-matter experts believed by CDISC to have sufficient knowledge and experience implementing the various CDISC standards. Glossary ADaM CDISC CRT-DDS LAB ODM SDS SDTM XML
Analysis Dataset Model Clinical Data Interchange Standards Consortium Case Report Tabulation Data Definition Specification Laboratory Data Model Operational Data Model Submission Data Standards Study Data Tabulation Model eXtensible Markup Language
